Keita Sasa, Raku Son, Akiko Oguchi, Karin Ashizawa, Nobuhiko Hasegawa, Daisuke Kubota, Yoshiyuki Suehara, Tatsuya Takagi, Taketo Okubo, Keisuke Akaike, et al. NTRK2 expression in gastrointestinal stromal tumors with a special emphasis on the clinicopathological and prognostic impacts. Scientific reports. 2024. 14. 1. 768-768
Keita Sasa, Tsuyoshi Saito, Taisei Kurihara, Nobuhiko Hasegawa, Kei Sano, Daisuke Kubota, Keisuke Akaike, Taketo Okubo, Takuo Hayashi, Tatsuya Takagi, et al. Retraction Note to: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma (Discover Oncology, (2021), 12, (57), 10.1007/s12672-021-00453-2). Discover Oncology. 2022. 13. 1
Keita Sasa, Tsuyoshi Saito, Taisei Kurihara, Nobuhiko Hasegawa, Kei Sano, Daisuke Kubota, Keisuke Akaike, Taketo Okubo, Takuo Hayashi, Tatsuya Takagi, et al. Retraction Note to: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma. Discover. Oncology. 2022. 13. 1. 20-20
Keita Sasa, Tsuyoshi Saito, Taisei Kurihara, Nobuhiko Hasegawa, Kei Sano, Daisuke Kubota, Keisuke Akaike, Taketo Okubo, Takuo Hayashi, Tatsuya Takagi, et al. Establishment of Rapid and Accurate Screening System for Molecular Target Therapy of Osteosarcoma. Technology in cancer research & treatment. 2022. 21. 15330338221138217-15330338221138217
Keita Sasa, Tsuyoshi Saito, Taisei Kurihara, Nobuhiko Hasegawa, Kei Sano, Daisuke Kubota, Keisuke Akaike, Taketo Okubo, Takuo Hayashi, Tatsuya Takagi, et al. IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma. Discover Oncology. 2021. 12. 1